Cell Therapy News 21.38 | Nov 2 2020

May 12, 2022

CTN 21.38 | Nov 2 2020

Cell Therapy News by STEMCELL Technologies

Vol. 21.38 – 2 November, 2020

TOP STORY

Intravenous Nanoparticle Vaccination Generates Stem-Like TCF1⁺ Neoantigen-Specific CD8⁺ T Cells

Using a self-assembling nanoparticle vaccine that links neoantigen peptides to a Toll-like receptor 7/8 agonist, researchers showed how the route and dose altered the magnitude and quality of neoantigen-specific CD8⁺ T cells.
[Nature Immunology]

Abstract

New human primary cell products—frozen leukopaks, regulatory T cells, and more. Click to view products.

PUBLICATIONSRanked by the impact factor of the journal

FoxO Maintains a Genuine Muscle Stem-Cell Quiescent State until Geriatric Age

In homeostatic skeletal muscle, scientists identified two quiescent stem-cell states distinguished by relative CD34 expression: CD34^High, with stemness properties, and CD34^Low, committed to myogenic differentiation.
[Nature Cell Biology]

Abstract

Exploration of Bacterial Bottlenecks and Streptococcus pneumoniae Pathogenesis by CRISPRi-Seq

To facilitate pathogenesis studies in vivo, scientists developed an inducible CRISPR interference system that enabled genome-wide fitness testing in one sequencing step
[Cell Host & Microbe]

Abstract Graphical Abstract

T Cell-Intrinsic Role for Nod2 in Protection against Th17-Mediated Uveiti

Scientists report a non-conventional, T cell-intrinsic function for Nod2 in suppression of Th17 immunity and experimental uveitis.
[Nature Communications]

Full Article

Synthesizing AND Gate Minigene Circuits Based on CRISPReader for Identification of Bladder Cancer Cells

Investigators constructed minigene circuits based on the CRISPReader, a technology used to control promoter-less gene expression in a robust manner.
[Nature Communications]

Full Article

Improvement of Islet Transplantation by the Fusion of Islet Cells with Functional Blood Vessels

Scientists introduced a novel strategy for the generation of prevascularized islet organoids by the fusion of pancreatic islet cells with functional native microvessels.
[EMBO Molecular Medicine]

Full Article

Targeted CRISPR Screening Identifies PRMT5 As Synthetic Lethality Combinatorial Target with Gemcitabine in Pancreatic Cancer Cellsescent State Until Geriatric Age

The authors performed an in vivo CRISPR screen in an orthotopic patient-derived xenograft model to identify gene targets whose inhibition created synergistic tumor growth inhibition with gemcitabine.
[Proceedings of the National Academy of Sciences of the United States of America]

Abstract

High-Throughput Continuous-Flow Microfluidic Electroporation of mRNA into Primary Human T Cells for Applications in Cellular Therapy Manufacturing

Investigators present a microfluidic continuous-flow electrotransfection device designed for precise, consistent, and high-throughput genetic modification of target cells in cellular therapy manufacturing applications.
[Scientific Reports]

Full Article

T Cell Optimized for Packaging (TOP) Vector: A New High-Titer Lentiviral Construct for Delivery of sgRNAs and Transgenes to Primary T Cells

Scientists describe the T-cell Optimized for Packaging (TOP) vector for delivering guide RNAs and transgenes into primary T cells
[Molecular Therapy-Methods & Clinical Development]

Abstract Graphical Abstract

The StemSpan™ T Cell Generation Kit is designed to promote differentiation of HSPCs into T cells in stroma- and serum-free culture conditions.

REVIEWS

Clinical CAR-T cell and Oncolytic Virotherapy for Cancer Treatment

Scientists provide an overview of the current clinical status of CAR-T and oncolytic virus (OV) therapies. While preclinical studies have demonstrated curative potential, the benefit of CAR-T and OVs as single agent treatments remains limited to a subset of patients.
[Molecular Therapy]

Abstract

Immune Checkpoint Molecules in Natural Killer Cells As Potential Targets for Cancer Immunotherapy

The authors focus on the recent findings concerning the roles of immune checkpoint molecules and receptors in the regulation of NK cell function, as well as their potential application in tumor immunotherapy.
[Signal Transduction and Targeted Therapy]

Full Article

INDUSTRY AND POLICY NEWS

EdiGene Announces IND Application for Its CRISPR/Cas 9 Gene-Editing Hematopoietic Stem Cell Therapy ET-01 in β-Thalassemia Accepted for Review by China National Medical Products Administration

EdiGene, Inc. announced the Center for Drug Evaluation of China National Medical Products Administration has accepted for review the company’s Investigational New Drug application for ET-01, autologous CD34+ hematopoietic stem/progenitor cells with the erythroid -specific enhancer of the BCL11A gene modified by CRISPR/Cas9, an investigational gene-editing therapy for patients with transfusion dependent β-thalassemia.
[EdiGene, Inc.]

Press Release

AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 To ImStem Biotechnology For Development Of Cell Therapy Candidate IMS001 For COVID-19 And Acute Respiratory Distress Syndrome

AgeX Therapeutics, Inc. and ImStem Biotechnology, Inc. announced that ImStem has obtained from AgeX a non-exclusive, royalty-bearing sublicense to use AgeX’s clinical-grade ESC line ESI-053 to derive ImStem’s investigational MSC product candidate IMS001 for development in COVID-19 as well as acute respiratory distress syndrome from other causes.
[AgeX Therapeutics]

Press Release

FEATURED EVENT

Intravenous Nanoparticle Vaccination Generates Stem-Like TCF1⁺ Neoantigen-Specific CD8⁺ T Cells

FoxO Maintains a Genuine Muscle Stem-Cell Quiescent State until Geriatric Age

Exploration of Bacterial Bottlenecks and Streptococcus pneumoniae Pathogenesis by CRISPRi-Seq

T Cell-Intrinsic Role for Nod2 in Protection against Th17-Mediated Uveiti

Synthesizing AND Gate Minigene Circuits Based on CRISPReader for Identification of Bladder Cancer Cells

Improvement of Islet Transplantation by the Fusion of Islet Cells with Functional Blood Vessels

Targeted CRISPR Screening Identifies PRMT5 As Synthetic Lethality Combinatorial Target with Gemcitabine in Pancreatic Cancer Cellsescent State Until Geriatric Age

High-Throughput Continuous-Flow Microfluidic Electroporation of mRNA into Primary Human T Cells for Applications in Cellular Therapy Manufacturing

T Cell Optimized for Packaging (TOP) Vector: A New High-Titer Lentiviral Construct for Delivery of sgRNAs and Transgenes to Primary T Cells

Clinical CAR-T cell and Oncolytic Virotherapy for Cancer Treatment

Immune Checkpoint Molecules in Natural Killer Cells As Potential Targets for Cancer Immunotherapy

EdiGene Announces IND Application for Its CRISPR/Cas 9 Gene-Editing Hematopoietic Stem Cell Therapy ET-01 in β-Thalassemia Accepted for Review by China National Medical Products Administration

AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 To ImStem Biotechnology For Development Of Cell Therapy Candidate IMS001 For COVID-19 And Acute Respiratory Distress Syndrome

Cell Symposia: 20 Years of the Human Genome: From Sequence to Substance

> See All Events

Process Development Lead – Gene Transfer

PhD Student – Adoptive T Cell Therapy of Cancer

Vice President – Oncology and Cell Therapy

Research Fellow Position – Neural Cell Therapy

Postdoctoral Researcher – Translational Neuroscience

> See All Jobs